Ascendia

 

  MARKET NEWS

Boehringer Ingelheim’s Investigational Asset Delivers Proteinuria Reduction in Phase II Kidney Trial
Halo Pharma to Become a Stand-Alone Drug Product Contract Development & Manufacturing Organization
Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic in Patients with Elevated Lp(a)
Vortex Biotech Opens New State-of-the-Art Laboratory at Manchester Science Park
Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation
iXCells Biotechnologies & Rosebud Biosciences Partner to Advance Organoid-Based Models for Rare Diseases
Medicus Pharma Announces Amendment to LifeArc License Improving Teverelix Long-Term Economic & Development Profile
Dosing Completed in the Phase I Clinical Trial of PulseSight Therapeutics’ Treatment for Dry AMD/Geographic Atrophy
Mendra Launches With $82 Million to Acquire, Develop & Commercialize Therapeutics for High Unmet Need Rare Diseases
Datwyler Launches Industry’s First 20mL Universal Plunger for Large-Volume On-Body Delivery

  EXPERT CONTENT & RESOURCES

Dr. Joseph Sinkule, Founder, Chairman of the Board and CEO of Klotho Neurosciences

Klotho Neurosciences: Focused on Neurodegenerative & Age-Related Disorders

Dr. Joseph Sinkule, CEO of Klotho Neurosciences, discusses the company, its therapies, the human Klotho gene, and longevity.

Operational Excellence at Scale: Why Integrated Manufacturing is the Future Biopharmaceutical Standard

Operational Excellence at Scale: Why Integrated Manufacturing is the Future Biopharmaceutical Standard

Pierre Catignol explains how the conventional model creates friction when the industry needs fluidity, and integrated manufacturing answers that call by converting logistical complexity into a reliable operating rhythm that clients trust.

Enabling a Breakthrough in Ophthalmology: A Case Study in Collaboration Between a Biotech & Device Manufacturer on a Novel Drug Delivery System

Enabling a Breakthrough in Ophthalmology: A Case Study in Collaboration Between a Biotech & Device Manufacturer on a Novel Drug Delivery System

Ashwin Agarwal, CFO of Azura Ophthalmics and John Merhige, Co-CEO of Credence MedSystems, share an inside look at how two partners are aligning technical and regulatory strategies, integrating complementary expertise, and collaborating effectively to deliver an innovative ophthalmic combination product and inform future biotech–device partnerships.

The AI-Driven Path to Precision Therapeutics

The AI-Driven Path to Precision Therapeutics

Drs. Rotem Gura-Sadovsky and Maayan Eilon-Ashkenazy explore the potential for AI to transform drug discovery, charting a path towards more targeted precision therapeutics.

  FEATURED EDITORIAL

  COMPANY PROFILE

HCmed Innovations is a CDMO specializing in inhalation drug delivery systems. Leveraging our proprietary vibrating mesh technology, we provide an integrated platform for the development of drug-device combination products, offering customized solutions for pharmaceutical partners. HCmed provides full-spectrum support from early-stage feasibility through clinical trials and commercial supply. Our integrated approach ensures alignment between drug formulation and device performance, allowing seamless transition across development phases. Whether optimizing aerosol characteristics or supporting regulatory submissions, we help partners de-risk development and shorten timelines for bringing combination products to market. Click here for more.

  WHITEPAPERS & WEBINARS

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.

CLICK HERE TO DOWNLOAD/VIEW THE …

WHITEPAPER - Effect of Excipient Choices on Topical Formulations & Manufacturing Processes

WHITEPAPER - Effect of Excipient Choices on Topical Formulations & Manufacturing Processes

In this whitepaper, we review the effect of excipient choice on the process of manufacturing topical products. The effect of the following excipient types will be discussed: surface active agents, preservatives, polymer choice and skin penetration enhancers.

Considerations include the …

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

 

The biopharmaceutical classification system classifies drugs according to their permeability and solubility. Drugs with poor solubility and/or permeability are class II or IV type drugs, and these require special formulation technologies for solubility enhancement. In the past 25 …

WHITEPAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations

WHITEPAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations

Abstract

Intradermal delivery has long been a critical method in medical and pharmaceutical fields, offering unique advantages for diagnosis, vaccination and therapeutic applications. This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 4 – Analytical Testing
February 11 – Injection Devices